PharmaLeaders: Global Pharmaceutical Market Benchmark Report – Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies

Pages: 376 Published: October 01, 2014 Report Code: GDHC005PLR

The Global Pharmaceutical Market Benchmark Report applies GlobalData’s proprietary ranking methodology to compare the competitive positions of 30 leading drug companies on 25 financial metrics. These companies are analyzed based on financial performance, cost-containment, capital structure, and firm utilization to illustrate the different strategies these companies are using to increase value for their shareholders and create a competitive advantage. Throughout the report, GlobalData’s Industry Dynamics Team provides expert insight, expanding on each of the metrics discussed. In addition to the financial metrics, this report discusses trends impacting the pharmaceutical marketplace including FDA approvals, patent/generic erosion, regulatory changes, and the impact of the ACA on Rx, along with partnering and acquisition activity, and operations strategy. The report also provides a drill-down analysis identifying the revenue and growth leaders across 4 geographic regions (US, EU, Japan/Asia, and Emerging markets), and 11 therapeutic franchises. Lastly, this report provides GlobalData’s outlook on the Global Pharmaceutical market, and each company’s future competitive position including six-year forecasts for all 30 companies covered in the report.

Scope

This report provides analysis of the key drivers and trends shaping the global pharmaceutical market; including drivers of financial growth and R&D spending, FDA approvals, generic erosion, corporate strategy, orphan drugs and asset value creation

This report offers a deep dive into the synergies behind partnering and acquisition activity

Covers 11 therapeutic franchises; market sizing, growth rates, company share, sales drivers of top drugs, pipeline movements, sales forecasts and product NPVs

Assessments of company financials by revenue, margin, expense and capital structure

Revenue and growth leaders across 4 geographies; US, EU, Japan/Asia, Emerging markets

Firm utilization, efficiency metrics, capital ratios, headcount analytics

Reasons to Buy

N/A

Key Players

Abbott
AbbVie
Allergan
Amgen
Astellas
AstraZeneca
Baxter
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Eisai
Eli Lilly
F. Hoffmann-La Roche
Gilead
GlaxoSmithKline
Johnson & Johnson
Merck
Merck KGaA
Novartis
Novo Nordisk
Otsuka
Pfizer
Regeneron (Eylea sales only)
Sanofi
Shire
Takeda
Teva
and UCB.

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Report Scope

2.1.1Company Covereage

2.1.2Therapy Franchise Coverage

2.2Upcoming Reports

2.3Recently Published Reports

2.4GlobalData’s Benchmarking Methodology

2.5Benchmark Leader: Pfizer

3Global Pharmaceutical Market Dynamics

3.1Sector Overview

3.1.1Peer Group Growth Rate

3.1.2Peer Group R&D Spending

3.2Corporate Valuations

3.2.1Market Capitalization

3.2.2Top 30 Pharma Valuations Compared Against the S&P500

3.3FDA Approved 27 Novel New Drugs in 2013

3.3.1From 2004 through 2013, CDER has Averaged 26 NME Approvals per Year

3.3.2Multiple Pathways for Accelerating Drug Approvals

3.3.3CDER Met or Exceeded PDUFA Goal Dates for All 27 NMEs Approved in 2013

3.3.4Drug Approvals Signify a Commercial Focus on High Growth Therapeutic Areas

3.3.5List of Approved NMEs in 2013

3.3.6GlobalData Sales Forecast for 2013 Approved Drugs

3.4New Approvals Drive Much Needed Value in the Pharmaceutical Market

3.4.1Exceptional Uptake of Sovaldi and Tecfidera Paves the way for New Optimism in Pharma

3.5Patent Cliff to Erode $65B in Sales by 2019

3.5.1Top 50 Patent Expiries

3.6Orphan Drugs: No Longer a Rare Opportunity

3.7Regulatory Notes

3.7.1FDA Issues Draft Guidance on Determination of Product Exclusivity for Biologics

3.7.2Federal Appeals Court Rules FDA Has Authority to Regulate Stem Cells

4Collaboration and Acquisition Strategies

4.1Deal Values Soar Due to Shire Acquisition

4.2Deep Dive: AbbVie Acquires Shire as the Threat of Humira Biosimilars Looms

4.2.1Deal Terms

4.2.2Combined Entity Holds Promise for AbbVie

4.2.3Tax Inversion Impact on Humira Cash Flow

4.2.4Shire Purchase Softens the Impact of AbbVie’s Maturing Portfolio

4.2.5Acquisition Reduces AbbVie’s Dependency on Humira Sales

4.2.6Shire Sales Forecasts and Portfolio Valuation

4.3M&A Analysis

4.3.1Roche Makes Respiratory Play with InterMune Buy

4.3.2AstraZeneca Rejects Pfizer’s Takeover Bid

4.3.3Teva Acquires Novel Migraine Prophylaxis Treatment

4.3.4Valeant’s Business Model Not Conducive for Allergan

4.3.5Shire Boosts Rare Disease Pipeline

4.3.6BMS Acquires Neuro Firm iPierian

4.3.7Amgen Dives into Multiple Myeloma Market, Gains Rights to Kyprolis

4.3.8Bayer Buys-Out Cancer Partner Algeta, Purchases Conceptus

4.3.9AZ Strengthens Respiratory Portfolio

4.3.10J&J Pays Big for Aragon’s Lead Pipeline Candidate

4.3.11Allergan Enhances Leadership Position in Neurology

4.3.12Astex Deal Might Stem the Bleeding for Otsuka

4.3.13Select Generic M&As

4.4Licensing and Partnerships

4.4.1BMS on a Shopping Spree for Cancer Immunotherapies

4.4.2Bayer Scoops-Up Orion’s Phase III Prostate Cancer Drug

4.4.3GSK Signs Deal with Adaptimmune to Develop T-cells

4.4.4Celgene: A Licensing Machine

4.4.5Novartis Pens Deal for Ophthotech’s Wet-AMD Treatment Fovista

4.4.6Merck Inks Potential Mega Deal with Ablynx, Sells-Off Eye Drugs

4.4.7Biogen Forges Preclinical Alzheimer’s Pact with Proteostasis

4.4.8Roche Turns on the Switch in Epigenetics

5Financial Management

5.1Global Pharmaceutical Market Competitive Landscape Assessment

5.1.1The Drug Sector Began to Show Signs of Stabilization in 2013

5.2Financial Management: Heat Map

5.2.1Gilead was the Financial Management Leader in 2013

5.3Financial Performance Metrics

5.3.1Revenue

5.3.2Revenue Growth YtY

5.3.3Operating Income

5.3.4Operating Income Growth YtY

5.3.5Operating Margin

5.3.6Operating Income per FTE

5.3.7Net Margin

6Expense Management

6.1Global Pharmaceutical Market Competitive Landscape Assessment

6.1.1Consistent Cost Structures Give Drugmakers Margin Stability

6.1.2Eisai Pushes Arena’s Belviq with More Reps and Ad Spending

6.2Expense Management: Heat Map

6.2.1Eisai was the Expense Management Leader in 2013

6.3Expense Performance Metrics

6.3.1S,G&A Spending

6.3.2S,G&A Spending as a Percentage of Revenue

6.3.3S&M Spending

6.3.4R&D Spending

6.3.5R&D Spending Growth

6.3.6R&D Spending as a Percentage of Revenue

7Therapy Franchise Analysis

7.1Cardiovascular

7.1.1Commercial Landscape

7.1.2Pipeline Highlights

7.2CNS

7.2.1Commercial Landscape

7.2.2Pipeline Highlights

7.3Diabetes

7.3.1Commercial Landscape

7.3.2Pipeline Highlights

7.4Gastrointestinal

7.4.1Commercial Landscape

7.4.2Pipeline Highlights

7.5Hematology

7.5.1Commercial Landscape

7.5.2Pipeline Highlights

7.6Immunology

7.6.1Commercial Landscape

7.6.2Pipeline Highlights

7.7Infectious Disease

7.7.1Commercial Landscape

7.7.2Pipeline Highlights

7.8Oncology

7.8.1Commercial Landscape

7.8.2Pipeline Highlights

7.9Ophthalmology

7.9.1Commercial Landscape

7.9.2Pipeline Highlights

7.10Respiratory

7.10.1Commercial Landscape

7.10.2Pipeline Highlights

7.11Vaccines

7.11.1Commercial Landscape

7.11.2Pipeline Highlights

8Regional Analysis

8.1North America Landscape Assessment

8.1.1Growth Driven by Biotechs and Specialty Pharma

8.2Regional Developments

8.2.1Gilead’s Price of Sovaldi May be a Pill too Tough to Swallow

8.2.2States’ Take Efforts into Their Own Hands to Limit the Influx of Opioids

8.3Revenue and Growth Leaders

8.3.1Revenue

8.3.2Revenue Growth YtY

8.4Europe Landscape Assessment

8.4.1AstraZeneca Pulls Down EU Market

8.5Regional Developments

8.5.1Merck KGaA Targets Italian Production Site for Investment

8.5.2Pfizer Partners with UK Academics to Develop Rare Disease Drugs

8.5.3Bayer’s Eylea Hits Road Block in Germany

8.6Revenue & Growth Leaders

8.6.1Revenue

8.6.2Revenue Growth YtY

8.7Asia-Pacific Landscape Assessment

8.7.1Astellas Pharma was the Growth Leader in Asia

8.8Regional Developments

8.8.1China Targets Big Pharma in Corruption Investigation

8.8.2UCB Secures Asian Marketing Rights to Biogen’s MS Drugs

8.8.3Merck KGaA Targets China with Allergy and Diabetes Plants

8.9Revenue & Growth Leaders

8.9.1Revenue

8.9.2Revenue Growth YtY

8.10Japan Landscape Assessment

8.10.1Daiichi Sankyo Trumps its Domestic Rivals

8.11Revenue & Growth Leaders

8.11.1Revenue

8.11.2Revenue Growth YtY

8.12Emerging Markets Landscape Assessment

8.12.1Differences in Regulatory and Commercialization Pathways Makes BRICs More Difficult than Previously Thought

8.13Regional Developments

8.13.1India to Receive Deep Discount on Sovaldi Price

8.13.2Pharma Furious Over Compulsory Licensing in India

8.13.3India Commits $500M to Doubling its Regulatory Force

8.13.4Abbott Grows Footprint in Latin America with CFR Buy

8.13.5GSK to Freeze Vaccine Prices for Developing Countries

8.13.6Drug Manufacturers Look to the Middle East for Untapped Opportunities

8.14Revenue & Growth Leaders

8.14.1Revenue

8.14.2Revenue Growth YtY

9Resource Management Strategies

9.1Human Capital Management

9.1.1Headcount Analysis

9.1.2Layoffs in 2013

9.2Drugmakers Expand Manufacturing Capacity for Biologics

9.2.1Roche Ramps up Production in Switzerland

9.2.2Drugmakers Advance into Asia to Grab Share

9.2.3Eisai Plans Major Sales Push in Russian Market

9.2.4Daiichi Unloads Ranbaxy Problems to Sun Pharma

9.3Firm Utilization: Heat Map

9.3.1Pfizer was the Firm Utilization Leader in 2013

9.4Firm Utilization Metrics

9.4.1Headcount Growth YtY

9.4.2Revenue per Employee

9.4.3R&D Expense per R&D Employee

9.4.4G&A Expense per G&A Employee

9.4.5S&M Expense per S&M Employee

9.5Capital Management: Heat Map

9.5.1Allergan was the Capital Management Leader due to its Higher Liquidity

9.6Capital Structure Metrics

9.6.1Debt/Equity

9.6.2Sales/Assets

9.6.3Return on Capital Employed

9.6.4Cash Ratio

9.6.5Current Ratio

9.6.6Quick Ratio

10Future Outlook

10.1Global Pharmaceutical Market

10.2Company Forecasts

11Market Data

11.1Global Pharmaceutical Market

11.1.1Pharmaceutical Revenue Forecast for 128 Leading Companies

11.2Pipeline Analysis

11.2.1Forecasts & Valuations

11.3Company Pipeline Profiles

11.4Molecule Type

11.4.1Biologics Versus Small Molecules

12Appendix

12.1Research Methodology

12.1.1Coverage

12.1.2Secondary Research

12.2About the Author

12.2.1Adam Dion, Industry Analyst

12.3Director, Healthcare Industry Dynamics

12.4Global Head of Healthcare

12.5About the Industry Dynamics Team

12.6About GlobalData

12.7Disclosure Information

12.8Contact Us

12.9Disclaimer

List of Tables

Table 1: GlobalData Benchmark Rankings, Global Pharmaceutical Market, 2013

Table 2: GlobalData Benchmark Rankings (cont’d), Global Pharmaceutical Market, 2013

Table 3: List of Approved New Molecular Entities, 2013

Table 4: Sales Forecast ($m) for Recently Approved Drugs, 2013

Table 5: Top 50 Patent Expiries, Sales ($m), 2013–2019

Table 6: Financial Management Composite Scores, 2013

Table 7: Expense Management Composite Scores, S,G&A, 2013

Table 8: Expense Management Composite Scores, R&D, 2013

Table 9: Therapy Franchise Market Outlook ($m) and Compound Annual Growth Rate, 2010–2019

Table 10: Top Largest Layoffs, 2013

Table 11: Firm Utilization Composite Scores, 2013

Table 12: Firm Utilization Composite Scores (cont’d), 2013

Table 13: Capital Management Composite Scores, Debt & Profitability Ratios, 2013

Table 14: Capital Management Composite Scores, Debt & Profitability Ratios, 2013

Table 15: Capital Management Composite Scores, Liquidity Ratios, 2013

Table 16: Capital Management Composite Scores, Liquidity Ratios, 2013

List of Figures

Figure 1: Combined Peer Group Revenue ($m) and Average Operating Margin, 2010–2013

Figure 2: Combined Peer Group R&D Spend ($m), 2010–2013

Figure 3: Total Market Capitalization ($bn), 2010–2014

Figure 4: Market Capitalization ($bn) by Company, 2014

Figure 5: Change in Market Capitalization ($bn) by Company

Figure 6: Top 30 Pharmaceutical Companies Valuation vs. S&P500

Figure 7: Number of NME Approvals and Applications Filed, 2004–2013

Figure 8: Percentage of NMEs by Approval Pathway, 2011–2013

Figure 9: Percentage of NMEs Approved First in the US and on First Cycle of Review, 2011–2013

Figure 10: Combined Revenue Projections of 2013 FDA Approvals vs. 2012 FDA Approvals ($m), 2012–2019

Figure 11: First Full-Year Sales ($m) of Major Product Launches by Year, 2009–2013

Figure 12: Revenue Projections for 2013 FDA Approvals ($m), 2013–2019

Figure 13: Patent Cliff Sales ($m) Erosion, 2013–2019

Figure 14: Percentage of Biosimilar Exposure on Company Revenues, 2013

Figure 15: Orphan Peer Group ($m) and Compound Annual Growth Rate, 2010–2019

Figure 16: Leading Orphan Drug Sales ($m), 2013 vs. 2019

Figure 17: Global Pharmaceutical Market, Total Deals and Deal Values ($m), 2009–2014

Figure 18: Number of M&A Deals and Deal Values ($m), 2009–2014

Figure 19: Number of Licensing Deals and Deal Values ($m), 2009–2014

Figure 20: M&A Deal Values ($m) by Company, 2004–2014

Figure 21: Licensing Deal Values ($m) by Company, 2004–2014

Figure 22: Projected Total Revenues ($m) for AbbVie/Shire Merger, 2014–2019

Figure 23: Tax Savings Impact of Shire Merger on Humira Cash Flow ($m), 2014–2029

Figure 24: Humira as a Percentage (%) of Total Sales Pre-and Post-Acquisition of Shire, 2014–2019

Figure 25: Potential Threat of Biosimilars on Humira Cash Flow ($m), 2014–2029

Figure 26: Combined Six-Year Forecast Revenues ($m) Across Shire’s Portfolio

Figure 27: Shire Leading Assets by Net Present Value ($m)

Figure 28: InterMune, Esbriet, Sales Forecast ($m), 2013–2019

Figure 29: Global Pharmaceutical Market Landscape Assessment – FY2013 Revenue Growth vs. Operating Margin

Figure 30: Revenue ($m) by Company, 2013

Figure 31: Revenue Growth by Company, 2013

Figure 32: Operating Income ($m) by Company, 2013

Figure 33: Operating Income Growth by Company, 2013

Figure 34: Operating Margin by Company, 2013

Figure 35: Operating Income per Employee, 2013

Figure 36: Net Margin by Company, 2013

Figure 37: Global Pharmaceutical Market Landscape Assessment – FY2013 S,G&A Expense vs. R&D Expense

Figure 38: S,G&A Spending ($m) by Company, 2013

Figure 39: S,G&A Spend as a Percentage of Revenue by Company, 2013

Figure 40: Sales and Marketing Spending ($m) by Company, 2013

Figure 41: R&D Spending ($m) by Company, 2013

Figure 42: R&D Spending Growth by Company, 2013

Figure 43: R&D Spending as a Percentage of Revenue by Company, 2013

Figure 44: Peer Group Rx Sales ($m) & Compound Annual Growth Rate, 2010–2019

Figure 45: Cardiovascular Market Size ($m) and Compound Annual Growth Rate, 2010–2019

Figure 46: Cardiovascular Market Share, 2013

Figure 47: Cardiovascular Market Share, 2010

Figure 48: Cardiovascular Drug Sales ($m), 2013 vs. 2019

Figure 49: CNS Market Size ($m) and Compound Annual Growth Rate, 2010–2019

Figure 50: CNS Market Share, 2013

Figure 51: CNS Market Share, 2010

Figure 52: CNS Drug Sales ($m), 2006–2019

Figure 53: CNS Drug Sales ($m), 2013 vs. 2019

Figure 54: Diabetes Market Size ($m) and Compound Annual Growth Rate, 2010–2019

Figure 55: Diabetes Market Share, 2013

Figure 56: Diabetes Market Share, 2010

Figure 57: Diabetes Drug Sales ($m), 2013 vs. 2019

Figure 58: Gastrointestinal Market Size ($m) and Compound Annual Growth Rate, 2010–2019

Figure 59: Gastrointestinal Market Share, 2013

Figure 60: Gastrointestinal Market Share, 2010

Figure 61: Gastrointestinal Drug Sales ($m), 2013 vs. 2019

Figure 62: Hematology Market Size ($m) and Compound Annual Growth Rate, 2010–2019

Figure 63: Hematology Market Share, 2013

Figure 64: Hematology Market Share, 2010

Figure 65: Hematology Drug Sales ($m), 2013 vs. 2019

Figure 66: Immunology Market Size ($m) and Compound Annual Growth Rate, 2010–2019

Figure 67: Immunology Market Share, 2013

Figure 68: Immunology Market Share, 2010

Figure 69: Immunology Drug Sales ($m), 2006–2019

Figure 70: Immunology Drug Sales ($m), 2013 vs. 2019

Figure 71: Infectious Diseases Market Size ($m) and Compound Annual Growth Rate, 2010–2019

Figure 72: Infectious Disease Market Share, 2013

Figure 73: Infectious Disease Market Share, 2010

Figure 74: Infectious Disease Drug Sales ($m), 2013 vs. 2019

Figure 75: Oncology Market Size ($m) and Compound Annual Growth Rate, 2010–2019

Figure 76: Oncology Market Share, 2013

Figure 77: Revlimid vs. MabThera/Rituxan Sales ($m), 2006–2019

Figure 78: Oncology Market Share, 2010

Figure 79: Oncology Drug Sales ($m), 2013 vs. 2019

Figure 80: Ophthalmology Market Size ($m) and Compound Annual Growth Rate, 2010–2019

Figure 81: Ophthalmology Market Share, 2013

Figure 82: Eylea vs. Lucentis Sales ($m), 2007–2019

Figure 83: Ophthalmology Market Share, 2010

Figure 84: Ophthalmology Drug Sales ($m), 2013 vs. 2019

Figure 85: Respiratory Market Size ($m) and Compound Annual Growth Rate, 2010–2019

Figure 86: Respiratory Market Share, 2013

Figure 87: Respiratory Market Share, 2010

Figure 88: Spiriva vs. Advair Sales ($m), 2006–2019

Figure 89: Respiratory Drug Sales ($m), 2013 vs. 2019

Figure 90: Vaccine Market Size ($m) and Compound Annual Growth Rate, 2010–2019

Figure 91: Vaccines Market Share, 2013

Figure 92: Vaccines Market Share, 2010

Figure 93: Vaccine Drug Sales ($m), 2013 vs. 2019

Figure 94: North America Landscape Assessment, 2013

Figure 95: North America Landscape Assessment (cont’d), 2013

Figure 96: North America Revenue ($m) by Company, 2013

Figure 97: North America Revenue Growth by Company, 2013

Figure 98: Europe Landscape Assessment, 2013

Figure 99: Europe Landscape Assessment (cont’d), 2013

Figure 100: Europe Revenue ($m) by Company, 2013

Figure 101: Europe Revenue Growth by Company, 2013

Figure 102: APAC Landscape Assessment, 2013

Figure 103: APAC Landscape Assessment (cont’d), 2013

Figure 104: APAC Revenue ($m) by Company, 2013

Figure 105: APAC Revenue Growth by Company, 2013

Figure 106: Japan Landscape Assessment, 2013

Figure 107: Japan Revenue ($m) by Company, 2013

Figure 108: Japan Revenue Growth by Company, 2013

Figure 109: Emerging Markets Landscape Assessment, 2013

Figure 110: Emerging Markets Landscape Assessment (cont’d), 2013

Figure 111: Emerging Markets Revenue ($m) by Company, 2013

Figure 112: Emerging Markets Revenue Growth by Company, 2013

Figure 113: Peer Group Headcount, Total, 2010–2013

Figure 114: Headcount by Company, 2013 vs. 2012

Figure 115: Peer Group Headcount, R&D, 2010–2013

Figure 116: R&D Headcount by Company, 2013 vs. 2012

Figure 117: Headcount Growth by Company, 2013

Figure 118: Revenue per Employee (In $ Thousands) by Company, 2013

Figure 119: R&D Expense per R&D Employee (In $ Thousands) by Company, 2013

Figure 120: G&A Expense per G&A Employee (In $ Thousands) by Company, 2012

Figure 121: S&M Expense per S&M Employee (In $ Thousands) by Company, 2013

Figure 122: Debt to Equity Ratio by Company, 2013

Figure 123: Sales to Assets Ratio by Company, 2013

Figure 124: Return on Capital Employed Ratio by Company, 2013

Figure 125: Cash Ratio by Company, 2013

Figure 126: Current Ratio by Company, 2013

Figure 127: Quick Ratio by Company, 2013

Figure 128: Pharmaceutical Benchmark Peer Group, Global Market Forecast, ($m), 2013–2019

Figure 129: Pharmaceutical Revenue Forecast ($m) by Peer Group, 2013 vs. 2019

Figure 130: Marketed and Pipeline Sales ($m) by Company, 2013

Figure 131: Percentage of Total Revenues, Pharma vs. Non-Pharma, 2013

Figure 132: Total Revenue ($m) Forecasts by Company, 2013 vs. 2019

Figure 133: Prescription Drug Sales ($m) Forecasts by Company, 2013 vs. 2019

Figure 134: Global Pharmaceutical Market Forecast ($m), 2013–2019

Figure 135: Marketed Product and Pipeline Sales Contributions ($m), 2019

Figure 136: Total Pharmaceutical Pipeline Revenue ($m), 2013–2019

Figure 137: Marketed vs. Pipeline Sales Contribution ($m), 2019

Figure 138: Pipeline Net Present Value ($m) by Company

Figure 139: Pipeline Sales ($m) by Company, 2019

Figure 140: AbbVie, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 141: Allergan, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 142: Amgen, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 143: Astellas, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 144: AstraZeneca, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 145: Baxter, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 146: Bayer, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 147: Biogen Idec, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 148: Boehringer Ingelheim, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 149: BMS, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 150: Celgene, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 151: CSL, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 152: Daiichi Sankyo, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 153: Eisai, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 154: Eli Lilly, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 155: F. H. La-Roche, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 156: Gilead, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 157: GSK, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 158: Johnson & Johnson, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 159: Merck, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 160: Merck KGaA, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 161: Novartis, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 162: Novo Nordisk, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 163: Otsuka, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 164: Pfizer, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 165: Sanofi, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 166: Shire, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 167: Takeda, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 168: Teva, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 169: UCB Pharma, Number of Clinical Trials, Phase and Therapy Area, 2014

Figure 170: Revenue Forecast ($m) by Molecule Type, Small Molecule vs. Biologics, 2019

Figure 171: Biologics Sales ($m) by Company, 2013

Figure 172: Percentage of Total Revenues, Biologics vs. Small Molecules, 2013

Figure 173: Biologics and Small Molecule Sales ($m) by Company, 2013

Figure 174: Net Present Value of Biologics Portfolio ($m) by Company, 2013

$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Pharmaceuticals
New
Net Present Value Model: (borneol + edaravone)
$500 | November 2022
Pharmaceuticals
New
Net Present Value Model: (Aspirin + Dipyridamole) ER
$500 | November 2022